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ABSTRACT
Objective Evaluate golimumab in patients with active
rheumatoid arthritis (RA) and previous tumour necrosis
factor-α (TNF) inhibitor use.
Methods Patients (n=461) previously receiving ≥1 TNF
inhibitor were randomised to subcutaneous injections of
placebo, golimumab 50 mg or golimumab 100 mg q4
weeks. Primary endpoint (≥20% improvement in
American College of Rheumatology (ACR20) criteria at
week 14) ﬁndings have been reported for all patients in
the trial. Reported herein are further assessments of
efﬁcacy/safety among patients receiving golimumab
+methotrexate (MTX).
Results Among efﬁcacy-evaluable patients who
received MTX at baseline, more receiving golimumab
+MTX (n=201) than placebo+MTX (n=103) achieved
ACR20 (40.8% vs 14.6%), ACR50 (20.9% vs 3.9%),
and ACR70 (11.4% vs 2.9%) responses at week 24.
Among the 137 patients who had received only one
prior TNF inhibitor (adalimumab, n=33; etanercept,
n=47; and inﬂiximab, n=57), week 24 ACR20 rates
were 30.3%, 46.8% and 50.9%, respectively, and thus
lowest among those who previously used adalimumab.
ACR20 response rates were 44.5% (61/137), 36.2%
(17/47) and 23.5% (4/17) among patients who had
received one, two or three TNF inhibitors, respectively.
Adverse event (AE) rates were comparable across type/
number of prior anti-TNF agents, but appeared
somewhat higher among patients who discontinued
previous TNF inhibitor(s) due to intolerance (37/49,
75.5%) versus lack of efﬁcacy (LOE, 113/191, 59.2%).
Conclusions Patients with active RA previously treated
with ≥1 TNF inhibitor had clinically relevant
improvement with golimumab+MTX, which appeared
somewhat enhanced among those who received only
etanercept or inﬂiximab as their prior TNF inhibitor.
Golimumab+MTX safety appeared similar across
patients, regardless of TNF inhibitor(s) previously used,
with fewer AEs occurring among patients who
discontinued prior therapy for LOE.
More than a decade has passed since the initial
introduction of tumour necrosis factor-α (TNF)
inhibitors, which have greatly expanded treatment
options for patients with rheumatoid arthritis
(RA).1 Given that patients may not always respond
to the ﬁrst TNF inhibitor prescribed and that there
is long-term experience with using other TNF inhi-
bitors, it is reasonable to assume that, in line with
recent disease management recommendations,2 3
clinicians will be treating increasing numbers of
patients exposed previously to one or more TNF
inhibitor(s).
Results of several small case series, open-label
studies and registries have indicated that patients
who switched from one TNF inhibitor to another
resulting from lack of efﬁcacy or intolerance may
respond to a second or even third TNF inhibitor.4–
9 Beneﬁts of switching from etanercept to inﬂixi-
mab, and vice versa, have been investigated.10–14
Additionally, the strategy of switching patients with
RA who are inadequately responsive to a TNF
inhibitor to a biological agent with a different
mode of action has been compared with that of
switching to another TNF inhibitor in non-
randomised observational studies of data from
registries.6 15
To date, the results of several randomised con-
trolled trials (RCTs) investigating therapies targeted
against molecules other than TNF in patients with
RA who failed TNF-blockade have been pub-
lished.16–19 However, the GO-AFTER trial evalu-
ated the efﬁcacy of TNF inhibitor therapy after
prior TNF inhibitor use in an RCT.20 In the
GO-AFTER trial, not all patients were receiving
concomitant methotrexate (MTX), and the primary
clinical endpoint was evaluated at 14 weeks because
of ethical considerations, although secondary clin-
ical and co-primary functional endpoints were
assessed at 6 months in all patients.20 Some RCTs
of biological therapies for patients with RA with
prior TNF inhibitor use have typically studied the
biological agent in combination with MTX and
assessed primary endpoints at 6 months.16–20
Some,21 22 but not all,23 systematic reviews may
not have considered differences in trial design
when evaluating studies. Because some authors
have suggested that switching to another monoclo-
nal antibody rather than to an anti-TNF receptor
construct agent may be more efﬁcacious after
anti-TNF failure,15 especially if the prior TNF
inhibitor was discontinued due to lack of efﬁcacy,24
more detailed information on response rates to
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golimumab in patients who had previously received different
TNF inhibitors would inform the selection of candidates for
golimumab therapy.
To assess and compare the efﬁcacy and safety of golimumab
following discontinuation of one or more other TNF inhibitors
in a subgroup of patients and at a time point comparable to those
of most other RCTs of biological RA therapies, we examined
GO-AFTER trial data from a novel perspective. We present the
ﬁndings of post-hoc analyses of data obtained from patients with
active RA previously treated with one or more TNF inhibitor and
also receiving MTX after 6 months of study drug treatment in
that trial, as well as hypotheses for assessment in future studies.
METHODS
Patients
As detailed previously,20 eligible patients had RA for ≥3 months
prior to screening and active disease with ≥4 swollen and ≥4
tender joints (mean values: 16.6/66 and 29.8/68, respectively).
Patients had received one or more doses of etanercept, adalimu-
mab or inﬂiximab ≥8 (adalimumab, etanercept) or ≥12 (inﬂixi-
mab) weeks prior to receiving the ﬁrst dose of study agent.
Patients must not have had a clinically serious adverse reaction
to any of the prior anti-TNF agents. Previous anti-TNF treat-
ment could have been discontinued for any reason, and the
reason(s) for discontinuation were documented by the investiga-
tor as either lack of efﬁcacy, intolerance or ‘other’.
Procedures
Patients were randomised (1:1:1) to receive subcutaneous placebo,
golimumab 50 mg or golimumab 100 mg every 4 weeks.
Randomisation was stratiﬁed by investigational site and baseline
MTX use (yes/no). Patients and investigators were masked to
study treatment assignment; golimumab and placebo were sup-
plied in identical single-use vials. Concomitant MTX use was per-
mitted, but not required, if continued at a stable dose.
Patients in the placebo and golimumab 50-mg groups with
<20% improvement in both tender and swollen joint counts at
week 16 escaped early to receive golimumab 50 mg and
100 mg, respectively, at week 16 and week 20. Study medication
was not altered in the 100-mg group. Week 24 was the efﬁcacy
time point of interest in these post-hoc analyses.
Clinical response was assessed using the American College of
Rheumatology (ACR) criteria indicating ≥20%, 50% and/or 70%
(ACR20,25 ACR50 and ACR70) improvement, as well as by achieve-
ment of a good or moderate response according to the 28-joint
Disease Activity Score (DAS28) and/or DAS28 <2.6.26 27 DAS28
was determined using C reactive protein (CRP) and erythrocyte
sedimentation rate (ESR). Physical function was assessed using the
Health Assessment Questionnaire Disability Index (HAQ-DI),28
and a functional response was deﬁned as ≥0.25-unit improvement29
from baseline to week 24. Safety was evaluated by reviewing docu-
mentation of reported adverse events (AEs).
Data analysis
Prior anti-TNF therapy was summarised using descriptive statis-
tics by reason for discontinuation and by duration of prior TNF
inhibitor for patients who had taken only one prior TNF inhibi-
tor. Since patients could have received more than one TNF
inhibitor, the numbers of patients who had discontinued their
prior TNF inhibitor were also summarised by reason for discon-
tinuation using non-mutually exclusive prior TNF inhibitor ces-
sation categories.
Efﬁcacy analyses were performed using patients randomised
to receive golimumab who reported concomitant MTX use at
baseline (n=205). Efﬁcacy data from one North American site
were excluded from these analyses because of protocol viola-
tions identiﬁed during the Sponsor’s standard audit processes,
yielding 201 efﬁcacy-evaluable patients. Clinical outcomes by
prior anti-TNF treatment were summarised using descriptive sta-
tistics for randomised patients. The proportions of patients
achieving ACR20 and ACR50 responses, DAS28-CRP and
DAS28-ESR responses, DAS28-CRP and DAS28-ESR each
<2.6, and HAQ–DI response at week 24 were determined
among patients who previously had received only one anti-TNF
agent and discontinued the treatment for any reason. Clinical
response was similarly assessed among patients who had discon-
tinued prior anti-TNF therapy as a result of lack of efﬁcacy,
because of intolerance, or for ‘other’ reasons, as well as among
patients based on the number of previous TNF inhibitors
received. For patients who escaped early, efﬁcacy data from
week 16 were carried forward for analysis at week 24 to ensure
that the results were not biased by the increased dose of golimu-
mab that the patient received at week 16 or week 24.20
Summaries of AEs include only treated patients (n=204).
Data from patients who were treated at the site that was
excluded from efﬁcacy analyses are included in these safety sum-
maries. The overall incidences of AEs are summarised by prior
anti-TNF agent, as well as by the number of anti-TNF agents
received previously and by the reason(s) for discontinuation of
prior anti-TNF therapy.
RESULTS
Disposition of prior anti-TNF therapy
In the GO-AFTER trial, 461 patients were randomly assigned to
receive placebo (n=155), golimumab 50 mg (n=153) or golimu-
mab 100 mg (n=153) every 4 weeks.20 Baseline characteristics
for the MTX-treated subgroup of randomised patients (table 1)
were generally consistent with those of the overall study popula-
tion,20 although fewer MTX-treated patients tested positive for
rheumatoid factor at baseline than did patients with no MTX
use at baseline (table 1).
With the exception of shorter disease duration (8.5 vs
11.6 years, respectively; p=0.023) and more women patients
(90.9% (30/33) vs 70.2% (40/57), respectively; p=0.023)
among adalimumab-only versus inﬂiximab-only-treated patients,
no consistent baseline differences were observed across prior
TNF inhibitors (data not shown).
Without the 16 patients treated at the excluded site, 445 ran-
domised patients were available for efﬁcacy analyses, 304 of
whom were also receiving MTX at baseline. Two hundred and
one of them were randomised to golimumab and were also
receiving MTX (table 2); much smaller proportions of patients
were receiving sulfasalazine (4.9%) and/or hydrochloroquine
(7.4%) in addition to MTX. Among the efﬁcacy-evaluable
golimumab-randomised patients who were also receiving MTX,
137 had previously received only one TNF inhibitor (adalimu-
mab, n=33; etanercept, n=47; and inﬂiximab, n=57). For each
prior TNF inhibitor, the proportion of patients who discontin-
ued that agent because of lack of efﬁcacy was 2.5-fold to
11-fold greater than those who discontinued because of intoler-
ance (table 1). Overall, most patients received prior anti-TNF
therapy for ≥24 weeks (table 1).
Clinical improvement
All golimumab-randomised patients who were receiving MTX at
baseline
Among patients with active RA who were previously treated
with a TNF inhibitor, 40.8% of golimumab+MTX-treated
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patients and 14.6% of placebo+MTX-treated patients achieved
an ACR20 response at week 24. The ACR50 and ACR70
response rates were also higher among patients who received
golimumab+MTX (20.9% and 11.4%, respectively) than
among those who received placebo+MTX (3.9% and 2.9%,
respectively). Similar patterns of improvement were observed
when disease activity was assessed using the DAS28-CRP or the
DAS28-ESR and also when using achievement of a ≥0.25-unit
reduction in the HAQ-DI score to assess improvement in phys-
ical function (table 2).
All golimumab-randomised patients who were receiving MTX at
baseline and who had discontinued only one prior TNF inhibitor
Among efﬁcacy-evaluable, golimumab-randomised patients receiv-
ing MTX at baseline, 137 had previously received only one prior
TNF inhibitor (adalimumab, n=33; etanercept, n=47; inﬂiximab,
n=57). The proportion of patients who achieved an ACR20
response at week 24 was 30.3% among those who previously had
been treated only with adalimumab, 46.8% among those who
previously had been treated only with etanercept and 50.9%
among those who previously had been treated only with inﬂixi-
mab. A similar pattern of clinical response was observed when
ACR50 response criteria were applied (ﬁgure 1).
Also at week 24, the proportions of patients achieving
DAS28-CRP response (good/moderate) and DAS28-CRP <2.6
were 39.4% and 15.2%, respectively, among those who previ-
ously had been treated only with adalimumab, 61.7% and
14.9%, respectively, among those who previously had been
treated only with etanercept and 66.7% and 17.5%, respect-
ively, among those who previously had been treated only with
inﬂiximab. Similar patterns were observed for DAS28-ESR
response (good/moderate) and DAS28-ESR<2.6 (ﬁgure 1).
Improvement in physical function, as assessed by achievement
of a ≥0.25-unit reduction in the HAQ-DI score from baseline to
week 24, was fairly consistent across the three TNF inhibitors
used previously and was achieved by 48.5%, 53.2% and 56.1%
of patients who had received only adalimumab, etanercept or
inﬂiximab, respectively (ﬁgure 1).
Table 1 Summary of baseline characteristics* in randomised patients and previous TNF inhibitor use† among patients receiving MTX at
baseline
MTX use at baseline No MTX use at baseline
Placebo Golimumab Placebo Golimumab
Randomised patients*, n 107 205 48 101
Women 89 (83.2%) 160 (78.0%) 43 (89.6%) 75 (74.3%)
Age—years 54.8±12.94 53.5±12.23 54.8±13.50 54.4±11.07
Disease duration—years 12.4±8.94 11.2±8.34 12.3±10.96 12.0±9.19
Swollen joint count (0–66) 17.0±11.90 16.0±10.02 18.6±11.47 17.8±12.12
Tender joint count (0–68) 29.8±18.09 29.1±16.20 30.3±16.50 31.4±17.85
Rheumatoid factor positive 69 (67.0%) 137 (69.5%) 41 (85.4%) 76 (77.6%)
HAQ-DI (0–3) 1.6±0.58 1.4±0.63 1.6±0.71 1.7±0.68
CRP (mg/L) 20.8±31.70 19.4±30.62 20.2±31.59 24.6±33.94
ESR (mm h) 38.9±24.94 34.6±28.10 37.3±29.26 40.4±28.97
DAS28-CRP score 5.7±1.01 5.7±1.04 5.7±1.16 6.0±1.05
DAS28-ESR score 6.3±1.10 6.1±1.24 6.2±1.37 6.5±1.24
Number of Prior TNF inhibitors
1 TNF inhibitor 2 TNF inhibitors 3 TNF inhibitors
Golimumab-randomised MTX-treated patients†, n 137 47 17
Prior TNF inhibitor
Adalimumab only Etanercept only Infliximab only
Golimumab-randomised patients who received only
one prior TNF inhibitor†, n
33 47 57
Reason for discontinuation of prior TNF inhibitor
Lack of efficacy 22 (66.7%) 23 (48.9%) 22 (38.6%)
Intolerance 5 (15.2%) 2 (4.3%) 8 (14.0%)
‘Other’ reason‡ 6 (18.2%) 22 (46.8%) 27 (47.4%)
Distribution by duration of prior treatment, n
<4 weeks 2 5 2
≥4 to <12 weeks 8 12 4
≥12 to <24 weeks 7 3 4
≥24 to <36 weeks 5 5 3
≥36 to <48 weeks 1 2 8
≥48 weeks 10 20 36
% patients receiving therapy for ≥24 weeks 48.5% 57.4% 82.5%
Data presented are number (%) of patients or mean±SD unless otherwise noted.
*Baseline characteristics are summarised for all randomised patients with available data.
†Efficacy-related patient subgroups exclude patients from a single site due to violations at the study site identified during the Sponsor’s standard audit processes.
‡In the vast majority of patients, the ‘other’ reason for discontinuation of previous anti-TNF agent(s) was related to cost/insurance coverage.
CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; TNF,
tumour necrosis factor.
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Figure 1 Improvement in rheumatoid arthritis signs and symptoms and physical function in golimumab-randomised patients with baseline
methotrexate use by reason for discontinuations of prior TNF inhibitor use, including any reason (A), lack of efﬁcacy (B), intolerance (C) and ‘other’
reasons (D). ACR20, ACR50, at least 20% or 50% improvement according to the American College of Rheumatology response criteria; CRP, C
reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability
Index response (≥ 0.25-unit improvement); TNF, tumour necrosis factor.
Table 2 Summary of clinical efficacy at week 24* among efficacy-evaluable randomised patients receiving MTX at baseline†
Golimumab
Placebo 50 mg 100 mg Combined
Efficacy-evaluable randomised patients
receiving study agent+MTX, n
103 101 100 201
ACR20 response 15 (14.6%) 36 (35.6%) 46 (46.0%) 82 (40.8%)
ACR50 response 4 (3.9%) 20 (19.8%) 22 (22.0%) 42 (20.9%)
ACR70 response 3 (2.9%) 12 (11.9%) 11 (11.0%) 23 (11.4%)
DAS28-CRP response‡ 24 (23.3%) 49 (48.5%) 65 (65.0%) 114 (56.7%)
DAS28-CRP score <2.6 2 (1.9%) 12 (11.9%) 14 (14.0%) 26 (12.9%)
DAS28-ESR response‡ 27 (26.2%) 49 (48.5%) 67 (67.0%) 116 (57.7%)
DAS28-ESR score <2.6 1 (1.0%) 11 (10.9%) 16 (16.0%) 27 (13.4%)
HAQ-DI ≥0.25-unit improvement 35 (34.0%) 48 (47.5%) 54 (54.0%) 102 (50.7%)
Data presented are number (%) of patients unless otherwise noted.
*For patients who early escaped, efficacy data from week 16 were carried forward for analysis at week 24.
†Excludes patients from a single site due to violations at the study site identified during the Sponsor’s standard audit processes. These violations were not confirmed until after the
initial publication of trial results, thus resulting in minor numerical differences in response rates between the initial report20 and the current paper regarding patients treated with
golimumab+MTX.
‡DAS28-CRP/ESR score indicating a ‘good’ or ‘moderate’ response.
ACR20, ACR 50, ACR70, at least 20%, 50%, or 70% improvement according to the American College of Rheumatology response criteria; CRP, C reactive protein; DAS28, 28-joint
Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate.
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Among patients who discontinued prior TNF inhibitor treat-
ment because of lack of efﬁcacy, ACR20 response rates at week
24 were 36.4% for those who previously had been treated only
with adalimumab, 56.5% for those who previously had been
treated only with etanercept and 45.5% for those who previ-
ously had been treated only with inﬂiximab. Among patients
who discontinued previous TNF inhibitor treatment because of
intolerance, ACR20 response rates at week 24 were 20.0%,
50.0% and 62.5% for adalimumab, etanercept and inﬂiximab,
respectively, but sample sizes were small. Similarly, among those
who discontinued previous TNF inhibitor treatment for ‘other’
reasons, respective ACR20 response rates at week 24 were
16.7%, 36.4% and 51.9% for adalimumab, etanercept and
inﬂiximab, respectively (ﬁgure 1).
In table 3, clinical responses at week 24 are compared by the
number of TNF inhibitors that patients had received prior to
study entry. By most measures, improvement in clinical signs and
symptoms and in physical function appeared to be more robust
among patients who previously had received fewer TNF inhibi-
tors. However, the numbers of patients who had received two
(n=47) and three (n=17) prior TNF inhibitors were limited.
Adverse events
Safety ﬁndings for all patients enrolled in the GO-AFTER study
have been reported through week 2420 and also through up to
3 years of golimumab therapy.30 AEs were reported by 64.3%
of all MTX-treated patients. Among these, 75.5% of patients
who had been intolerant of prior therapy and 59.2% of those
who had an inadequate response to treatment with the prior
TNF inhibitor(s) reported AEs. The overall proportions of
patients developing AEs were similar among those treated with
either golimumab or placebo, when grouped by number of
prior TNF inhibitors received, speciﬁc prior TNF inhibitor
received or reason for discontinuation of that previous agent
(table 4).
The incidences of serious AEs and serious infections appeared
to be comparable across the subgroups of patients evaluated,
with the exception of a higher incidence of serious AEs among
patients who had received three (18.8%) prior TNF inhibitors,
compared with those who previously had received one (2.5%)
or two (3.8%) TNF inhibitors. However, interpretation of these
ﬁndings is limited by the small numbers of patients who experi-
enced serious AEs or serious infections (table 4).
DISCUSSION
Although data derived from several small case series, open-label
studies and registries have suggested that patients with RA
switched from one to another TNF inhibitor because of lack of
efﬁcacy or intolerance may respond to the second or even third
agent,4–9 such response patterns have not previously been exam-
ined in a randomised, controlled study. Using data from the
GO-AFTER trial,20 we evaluated the efﬁcacy and safety of goli-
mumab when switching from another TNF inhibitor among
more than 200 patients with active RA who previously received
adalimumab, etanercept and/or inﬂiximab and reported MTX
use at baseline. Our post-hoc data analyses indicate that among
patients taking MTX at baseline, the response rates at week 24
are somewhat higher than those reported previously for all
patients at the primary endpoint of week 14.20 This is consistent
with the generally accepted principle that concomitant use of
MTX with a TNF inhibitor results in better clinical and func-
tional outcomes.31–33 Moreover, patients who switch from ada-
limumab, etanercept or inﬂiximab to golimumab demonstrate
clinically relevant responses at week 24, regardless of whether
the prior TNF inhibitor was a monoclonal antibody or a soluble
receptor fusion protein.
Of note and consistent with results of a comparative
meta-analysis,23 although it is difﬁcult to compare outcomes
across clinical trials due to differences in trial design, week 24
ACR response rates among patients who had discontinued prior
anti-TNF therapy and received golimumab+MTX in
GO-AFTER are comparable to those observed at the same week
24 time point for other biological agents with different mechan-
isms of action in combination with MTX. For example, week
24 ACR50 response rates for study agent versus placebo, both
with concomitant disease-modifying antirheumatic drugs, were
27% and 5% for rituximab16; 29% (8 mg/kg), 17% (4 mg/kg)
and 4% for tocilizumab34; and 20% and 4% for abatacept.18
The most straightforward approach to assess effects of switch-
ing agents is to analyse data derived from patients previously
treated with only one prior TNF inhibitor. Despite our previ-
ously reported observations of clinically relevant responses to
golimumab in the overall trial population,20 patients previously
exposed to more than two TNF inhibitors appear to be less
likely to demonstrate marked improvement in clinical and func-
tional outcomes. ACR50 response rates were similar among
patients who had been treated with one or two prior TNF inhi-
bitors, but were much lower when golimumab was initiated as
the fourth TNF inhibitor. Although these ﬁndings suggest that
such patients might respond better to a biological agent with a
different mechanism of action, it should be considered that the
rates of response to each of rituximab and abatacept also
decrease with previous exposure to increasing numbers of TNF
inhibitors.35 36 Future studies employing biomarkers may help
to predict which patients are more likely to respond to the dif-
ferent agents, following initial exposure to a TNF inhibitor.
Because patients were not stratiﬁed by prior TNF inhibitor
use when randomised to treatment arms, the size of some of the
subgroups that were evaluated was small, and our subgroup
Table 3 Clinical response at week 24* among golimumab+
MTX-treated patients† by number of previous TNF inhibitor(s)
Number of previous TNF inhibitor(s)
1 TNF
inhibitor
2 TNF
inhibitors
3 TNF
inhibitors
Patients who discontinued one
or more previous TNF-inhibitor
for any reason, n
137 47 17
ACR20 response 61 (44.5%) 17 (36.2%) 4 (23.5%)
ACR50 response 30 (21.9%) 11 (23.4%) 1 (5.9%)
DAS28 response (good/
moderate)
DAS28-CRP 80 (58.4%) 24 (51.1%) 10 (58.8%)
DAS28-ESR 82 (59.9%) 24 (51.1%) 10 (58.8%)
DAS28 score <2.6
DAS28-CRP 22 (16.1%) 3 (6.4%) 1 (5.9%)
DAS28-ESR 23 (16.8%) 3 (6.4%) 1 (5.9%)
HAQ-DI ≥0.25-unit improvement 73 (53.3%) 22 (46.8%) 7 (41.2%)
Data presented are number (%) of patients unless otherwise noted.
*For patients who escaped early, efficacy data from week 16 were carried forward for
analysis at week 24.
†Excludes patients from a single site due to violations at the study site identified
during the Sponsor’s standard audit processes.
ACR20, ACR50, at least 20% or 50% improvement according to the American College
of Rheumatology response criteria; CRP, C reactive protein; DAS28, 28-joint Disease
Activity Score; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment
Questionnaire Disability Index; MTX, methotrexate; TNF, tumour necrosis factor.
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analyses were performed post-hoc, no formal statistical testing
was performed. Despite these limitations, the data reveal numer-
ical trends. For example, ACR20 response rates at week 24 for
patients treated with golimumab 50 or 100 mg and MTX were
numerically higher among those who switched from etanercept
(46.8%) or inﬂiximab (50.9%) compared with those who had
previously received adalimumab (30.3%), the agent most similar
in structure to golimumab.37 Conversely, the proportion of
patients who were previously treated with adalimumab for more
than 24 weeks was much lower than that of patients who had
previously received treatment with etanercept or inﬂiximab for
more than 24 weeks, which could have been due to a larger
number of patients with refractory disease among those receiv-
ing adalimumab treatment. It is possible that patients previously
treated with agents structurally more dissimilar to golimumab
developed antibodies to the prior TNF inhibitor that precluded
continued response to the previous agent38; these antibodies
might have been less likely to cross-react with the human goli-
mumab molecule, allowing a better subsequent response to goli-
mumab. The presence of antibodies to prior TNF inhibitor(s)
was not assessed in GO-AFTER. However, future studies of
switching among TNF inhibitors should include such assess-
ments to better characterise the mechanisms underlying differ-
ential responses to subsequent treatment.
The safety proﬁle of golimumab+MTX was similar to that of
placebo+MTX and was consistent among patients who previ-
ously received adalimumab, etanercept or inﬂiximab, and
among those who had received one, two or three prior TNF
inhibitors. When assessed by reason for discontinuation of pre-
vious anti-TNF agent(s), however, AEs appeared to be more
Table 4 MTX-treated patients with adverse events by number, type, and reason for discontinuation of previous TNF inhibitor(s) during the
placebo-controlled study period (weeks 0–16)
Placebo+MTX Golimumab+MTX All patients
All Adverse Events (AEs) 67/107 (62.6%) 133/204 (65.2%) 200/311 (64.3%)
All AEs by number of prior agents
1 TNF inhibitor 38/60 (63.3%) 93/140 (66.4%) 131/200 (65.5%)
2 TNF inhibitors 20/33 (60.6%) 28/46 (60.9%) 48/79 (60.8%)
3 TNF inhibitors 9/14 (64.3%) 12/18 (66.7%) 21/32 (65.6%)
All AEs by prior agent*
Adalimumab only 10/14 (71.4%) 21/34 (61.8%) 31/48 (64.6%)
Etanercept only 9/17 (52.9%) 31/49 (63.3%) 40/66 (60.6%)
Infliximab only 19/29 (65.5%) 41/57 (71.9%) 60/86 (69.8%)
All AEs by reason for d/c of agent†
Lack of efficacy 40/70 (57.1%) 73/121 (60.3%) 113/191 (59.2%)
Intolerance 13/16 (81.3%) 24/33 (72.7%) 37/49 (75.5%)
‘Other’ reason 24/40 (60.0%) 52/75 (69.3%) 76/115 (66.1%)
Serious Adverse Events (SAEs) 8/107 (7.5%) 6/204 (2.9%) 14/311 (4.5%)
SAEs by number of prior agents
1 TNF inhibitor 3/60 (5.0%) 2/140 (1.4%) 5/200 (2.5%)
2 TNF inhibitors 2/33 (6.1%) 1/46 (2.2%) 3/79 (3.8%)
3 TNF inhibitors 3/14 (21.4%) 3/18 (16.7%) 6/32 (18.8%)
SAEs by prior agent*
Adalimumab only 0/14 (0.0%) 2/34 (5.9%) 2/48 (4.2%)
Etanercept only 0/17 (0.0%) 0/49 (0.0%) 0/66 (0.0%)
Infliximab only 3/29 (10.3%) 0/57 (0.0%) 3/86 (3.5%)
SAEs by reason for d/c of agent†
Lack of efficacy 7/70 (10.0%) 4/121 (3.3%) 11/191 (5.8%)
Intolerance 1/16 (6.3%) 2/33 (6.1%) 3/49 (6.1%)
‘Other’ reason 1/40 (2.5%) 1/75 (1.3%) 2/115 (1.7%)
Serious Infections (SIs) 3/107 (2.8%) 2/204 (1.0%) 5/311 (1.6%)
SIs by number of prior agents
1 TNF inhibitor 2/60 (3.3%) 1/140 (0.7%) 3/200 (1.5%)
2 TNF inhibitors 1/33 (3.0%) 0/46 (0.0%) 1/79 (1.3%)
3 TNF inhibitors 0/14 (0.0%) 1/18 (5.6%) 1/32 (3.1%)
SIs by prior agent*
Adalimumab only 0/14 (0.0%) 1/34 (2.9%) 1/48 (2.1%)
Etanercept only 0/17 (0.0%) 0/49 (0.0%) 0/66 (0.0%)
Infliximab only 2/29 (6.9%) 0/57 (0.0%) 2/86 (2.3%)
SIs by reason for d/c of prior agent†
Lack of efficacy 2/70 (2.9%) 1/121 (0.8%) 3/191 (1.6%)
Intolerance 0/16 (0.0%) 1/33 (3.0%) 1/49 (2.0%)
‘Other’ reason 1/40 (2.5%) 1/75 (1.3%) 2/115 (1.7%)
Data presented are number (%) of treated patients.
*Among patients who received only one prior TNF inhibitor.
†Some patients had received more than one TNF inhibitor and could have discontinued each one for a different reason. In the vast majority of patients, the ‘other’ reason for
discontinuation of previous anti-TNF agent(s) was related to cost/insurance coverage.
d/c, discontinuation; MTX, methotrexate; TNF, tumour necrosis factor.
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common among patients who had discontinued prior anti-TNF
therapy because of intolerance than because of lack of efﬁcacy
or ‘other’ reasons. The incidences of serious AEs and serious
infections were low, but appeared comparable across patient
subgroups evaluated, except for a somewhat higher incidence of
serious AEs among patients who had received three (18.8%)
prior TNF inhibitors, compared with those who previously had
received one (2.5%) or two (3.8%) inhibitors. Overall, the
safety ﬁndings are not unexpected given that TNF inhibitors as
a class, regardless of the speciﬁc molecular construct, share
similar potential safety risks.37 39–41
This post-hoc subgroup analysis has several limitations. As
mentioned above, patient randomisation was not stratiﬁed by
the speciﬁc TNF inhibitor or by the number of TNF inhibitors
used previously. Subgroup sample size was small in some of
these comparisons. Also, patients enrolled into the GO-AFTER
trial could have discontinued their prior TNF inhibitor(s) for
any reason; reasons for discontinuation were categorised at the
discretion of the study investigator, as no formal deﬁnitions
were provided.
In conclusion, patients with active RA who previously
received TNF inhibitor therapy and were treated with golimu-
mab and concomitant MTX in the GO-AFTER trial demon-
strated clinically relevant improvement in disease activity and
physical function after switching to golimumab, regardless of
which TNF inhibitor had been taken previously. Of particular
note, patients who switched from either etanercept or inﬂiximab
appeared to exhibit better subsequent responses to golimumab
than those that were observed among patients who previously
had received adalimumab which, of the three prior TNF inhibi-
tors, is most structurally similar to golimumab. However,
further study is required to conﬁrm the current ﬁndings.
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